Departments of *Pathology and Diagnostics, †Surgery and Oncology, Medical Oncology Unit, University and Hospital Trust of Verona, Verona, Italy; ‡Cytomolecular Lab, Hartmann Institute, University of Helsinki, Finland; §Department of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Torino, Italy; and ‖ARC-NET Research Centre, University and Hospital Trust of Verona, Verona, Italy.
J Thorac Oncol. 2014 May;9(5):729-32. doi: 10.1097/JTO.0000000000000109.
The report of cases of lung squamous cell cancers harboring anaplastic lymphoma kinase (ALK) gene rearrangements raises the question whether this histologic subtype should be also evaluated for such molecular predictive test.
A consecutive series of 40 lung pure squamous cell carcinomas were analyzed for ALK gene status by fluorescence in situ hybridization. Squamous differentiation was validated using an immunohistochemical panel including n-p63 (p40), cytokeratin (CK) 5/6, sex-determining region Y (SRY)-Box2 (SOX2), thyroid transcription factor 1, CK7, and Napsin-A.
Squamous differentiation was confirmed in all tumors as they stained positive for n-p63 and CK5/6 and negative for thyroid transcription factor 1 and Napsin-A. One of 40 cases (2.5%) showed an ALK rearrangement on fluorescence in situ hybridization analysis.
ALK translocation may be found in lung pure squamous cell carcinomas. Our data suggest the opportunity to test ALK rearrangements on biopsy samples harboring squamous cell cancer differentiation.
报道了含有间变性淋巴瘤激酶（ALK）基因重排的肺鳞状细胞癌病例，这引发了一个问题，即是否也应针对这种组织学亚型进行此类分子预测性检测。
通过荧光原位杂交分析了连续 40 例肺纯鳞癌的 ALK 基因状态。使用包括 n-p63（p40）、细胞角蛋白（CK）5/6、性别决定区 Y（SRY）-盒 2（SOX2）、甲状腺转录因子 1、CK7 和 Napsin-A 的免疫组织化学组合来验证鳞状分化。
所有肿瘤均证实为鳞状分化，因为它们对 n-p63 和 CK5/6 呈阳性，对甲状腺转录因子 1 和 Napsin-A 呈阴性。40 例中有 1 例（2.5%）在荧光原位杂交分析中显示 ALK 重排。
ALK 易位可能存在于肺纯鳞癌中。我们的数据表明有机会在具有鳞状细胞癌分化的活检样本上检测 ALK 重排。
